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ABSTRACT 
 
Aims: To determine the molecular properties of common antihistamines and non-steroidal anti-
inflammatory agents (NSAIDs). To identify interrelationships among these two groups of drugs 
utilizing pattern recognition methods and statistical analysis. 
Study Design: After determination of molecular properties, values thereof are examined using 
pattern recognition methods and other numerical analysis for underlying relationships and 
similarities. 
Place and Duration of Study: Durham Science Center, University of Nebraska, Omaha, Nebraska 
from September 2016 to January 2017. 
Methodology: Thirty compounds were identified as antihistamines and 27 compounds identified as 
NSAIDs. Properties such as Log P, molecular weight, polar surface area, etc. are determined.  
Molecular properties are compared applying methods such as K-means cluster analysis, nearest 
neighbor joining, box plots, and statistical analysis in order to determine trends and underlying 
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relationships. Pattern recognition techniques allow elucidation of underlying similarities. 
Results: The molecular properties of all 57 drugs are tabulated for comparison and numerical 
analysis. Evaluation by Kruskal-Wallis test and one-way ANOVA indicated that antihistamines and 
NSAIDs’ values of Log P have equal medians and equal means. However, values of polar surface 
area (PSA) and number of rotatable bonds for these two groups do not have equal means and 
medians. Box plots indicated that Log P, PSA, and molecular weight values have significant 
overlap in range. Neighbor-joining method showed which drugs are most similar to each other.  K-
means cluster analysis also divided these 57 drugs into six groups of highest similarity.  Principal 
coordinates analysis (PCoA) with 95% ellipses indicated all but four of the drugs fall within a 95% 
confidence region. Multiple regression analysis generated mathematical relationship for prediction 
of new drugs.  
Conclusion:  These two groups of drugs show compelling similarities. PCoA showed all but four of 
57 drugs come within a 95% confidence ellipsis. Neighbor joining and K-means cluster analysis 
showed drugs having similarities between the two groups. 
  
 
Keywords: Antihistamines; non-steroidal anti-inflammatory drugs; pattern recognition. 
 
ABBREVIATIONS 
  
PSA: polar surface area; nOHNH: number of hydroxyl groups and amine groups; nON: number of 
oxygen and nitrogen atoms; nRotB: number of rotatable bonds; MV: molecular volume; nAtoms: 
number of atoms; MW: molecular weight; RO5: rule of five.  
 
1. INTRODUCTION  
 
The group of drugs referred to as non-steroidal 
anti-inflammatory agents (NSAIDs) are applied in 
the treatment of fever, pain, acute and chronic 
inflammatory conditions [1]. They are considered 
to be chemically heterogeneous and inhibit the 
intracellular cyclo-oxygenase enzymes COX-1 
and COX-2 to reduce the synthesis of 
prostaglandins [1]. Generally, NSAIDs are highly 
bound to plasma proteins such as albumin, which 
decreases their body distribution to levels, 
considered low (i.e. as low as or lower than 0.2 
Liter/kg) [2]. The renal excretion of the 
unchanged NSAID is generally less than 5% of 
the given dose, therefore, elimination                  
depends greatly on hepatic biotransformation        
[2]. The majority of NSAIDs are nonselective 
inhibitors of COX-1 and COX-2 as a 
competitively reversible mechanism (except               
for aspirin which is irreversible inhibition),          
but still act as antipyretic agents to reduce fever 
[3].   
 
Most of the NSAIDs are metabolized by oxidation 
and conjugation to inactive metabolites in the 
liver [1,2,3]. Most NSAIDs are weak acids that 
have a pKa ranging from 3 to 5 [3]. The range of 
medical conditions that NSAIDs are applied for 
clinical treatment is quite broad, and includes 
[2,3,4]: Osteoarthritis, rheumatoid arthritis, low 
back pain, headache, acute gout, metastatic 
bone pain, renal colic, pyrexia, and macular 
edema.  NSAIDs and antihistamines are used as 
therapy for ocular allergy [5], NSAIDs for 
beneficial effects for patients with colorectal 
cancer [6], and gastric pain relief with protective 
agents [7]. However, NSAIDs use has safety 
concerns [8], increased sepsis following 
colorectal surgery [9], association with 
hypertension [10], and increased risk of stroke 
[11]. Interestingly, stress has been shown to be 
an independent factor for ulcers, compared to H 
pylori or NSAIDs exposure [12,13]. Antihistamine 
use concurrent prevents to the appearance of 
NSAIDs induced urticarial and/or angioedema 
[14]. 
 
Hypersensitivity reactions, or allergic reactions, 
are highly frequent and represent a public health 
issue of importance and significant expense [15]. 
Various allergic reactions, like those to peanuts, 
shellfish, or eggs, are a serious form of reaction 
affecting the respiratory organs that can cause 
loss of consciousness and sometimes death [16]. 
The World Health Organization estimates that as 
many as 300 million people suffer from asthma 
[17]. The symptoms and effects of allergic 
reactions can vary widely from person to person, 
which falls into the study of epigenetics [18]. 
Individuals having both parents with allergies are 
70% likely to suffer allergies, while that figure 
reduces to 48% for only one parent having 
allergies [19].  
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There are four major groups of histamine 
receptors (H1, H2, H3, and H4), with the H1 
receptors most important in chronic urticarial    
and allergic rhinitis [20]. Second-generation 
antihistamines (such as fexofenadine) have 
decrease lipophilic structures and do not cross 
the blood-brain barrier (BBB), as do the first-
generation antihistamines [20]. Interestingly, 
antihistamines that cross the BBB can have both 
stimulant and depressant effects [4]. Second-
generation antihistamines developed as H1 
blockers, have fewer side effects [20]. The H1 
targeting antihistamines are the major means for 
treatment of urticaria (hives) [21].  
 
Histamine released into the blood following the 
action of an allergen binds to receptors of various 
tissue resulting in constriction of the bronchi, 
dilation of blood vessels (inducing fall in blood 
pressure), increases permeability of blood 
vessels, and increases the production of 
hydrochloric acid in the stomach [22].  
Antihistamines counteract the effects mediated 
by histamine, but in themselves can bring about 
unwanted side effects such as weight gain, urine 
retention, dizziness, and increased risk for 
ventricular arrhythmias [22,23]. The sedative 
effect of the first-generation antihistamines that 
gained for themselves attention and notoriety 
[24]. Research aimed towards H3 and H4 
receptors in disease is a strong area of research 
[25,26]. Research in the area of H3 receptors 
may contribute to treatments for obesity, mental 
health problems, and inflammatory disease 
[27,28]. This study introduces analysis of the 
relative structures of NSAIDs and antihistamines.  
Underlying relationships found within their 
molecular properties leads to further 
understanding of pharmacokinetics and 
prediction of new structures. 
 
2. METHODOLOGY  
 
2.1 Properties and Molecular Modeling 
 
For all drugs included in this study, the numerical 
values of molecular properties were determined 
by utilizing heuristic techniques of Molinspiration 
(Molinspiration Cheminformatics, Nova ulica 61, 
SK-900 26 Slovensky Grob, Slovak Republic).  
Elucidation of molecular structure components 
was accomplished by use of ACD ChemSketch 
Modeling v. 12.01 (Advanced Chemistry 
Development, 110 Yonge Street, Toronto 
Ontario, M5C 1T4 Canada) and Molinspiration 
(http://www.molinspiration.com/services/search.h
tml). 
2.2 Pattern Recognition and Multivariate 
Statistical Analysis 
 
Identification of underlying associations and 
patterns within the numerical values of molecular 
properties was accomplished by use of pattern 
recognition techniques. This included analysis by 
non-hierarchical K-means cluster analysis, 
neighbor joining method, principal coordinates 
analysis with 95% ellipses, these performed by 
PAST v. 2.06 (copyright Oyvind Hammer, D.A.T. 
Harper 1999-2008). 
 
2.3 Various Statistical Analysis Data 
 
Various methods of statistical analysis applied 
included Pearson r correlation, descriptive 
statistics by Microsoft EXCEL v. 14.0.6112.5000 
(EXCEL Professional plus 2010). 
 
Algorithmic software by GraphPad accomplished 
multiple regression analysis of molecular 
property values (Instat version 3.00, GraphPad 
Software, Inc., San Diego, California USA; 
www.graphpad.com). Determination of any 
numerical outliers accomplished by Grubb’s test 
(also known as extreme studentized deviate).  Box 
plots, Kruskal-Wallis test, one-way ANOVA, and F 
and T tests were accomplished by PAST v. 2.06. 
 
3. RESULTS AND DISCUSSION 
 
3.1 Structure Features and Properties 
 
Important groups of drugs that provide 
substantial public health impact would certainly 
include NSAIDs (ATC code MO1) and 
anithistamines (ATC code RO6). Great interest in 
drugs that would be able to antagonize the action 
of histamine arose in clinicians concerned about 
the treatment of diseases in which histamine 
played an important role [4]. The antipyretic 
activity of willow bark discerned in the 19th 
century and scarcity prompted the need for 
synthetic alternates [4]. The appearance of 
second-generation antihistamines that avoided 
undesirable side effects of first-generation drugs 
provided a successful alternative for clinicians. 
The search and design of novel NSAIDs and 
antihistamines continues, although significant 
harmful side effects discerned in promising 
candidates gives pause to the progress made.  
 
Drug discovery is complex and exacting pursuit 
of beneficial agents to enhance medicine. A 
broadly accepted result of the study is the 
importance of optimizing the absorption, 
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distribution, metabolism, excretion, and toxicity 
(ADME/Tox) properties of candidates in addition 
to their pharmacology (e.g., efficacy, selectivity) 
to obtain success [29]. Drug-like properties are 
an integral part of novel drug discovery [4]. The 
rule of five (RO5), is a set of guidelines to 
evaluate drug likeness or determine if a chemical 
compound with a certain pharmacological or 
biological activity has properties that would   
make it a likely orally active drug in humans               
[29]. This rule of five will be determined for                 
the representative sets of NSAIDS and 
antihistamines examined for this study. The 
structures of 18 H1 antagonist agents are 
presented in Fig. 1 for comparison, showing 
structure features in common and descriptive of 
antihistamines. 
 
Seasonal allergies are often treated with 
pharmaceutical agents that block H1 receptors, 
thereby competing with histamine for binding to 
sites (H1 antagonists) [22]. Shown in Fig. 1, each 
compound has at least two simple aromatic rings 
or aromatic ring plus heterocyclic aromatic ring, 
with an amine group (in or out of ring). H1-
antihistamines will readily cross the BBB and 
result in sedation [20,21]. Various molecular 
properties associated with each drug 1 to 18, as 
well as drugs 19 to 30 (see Fig. 2) for all 
antihistamines (ATC  code RO6), and 31 to 57 
for all NSAIDs (ATC code MO1A), shown in 
Table 1. 
 
Structure features common to H1 antagonists 
include at least two aromatic rings, but the ring 
may be a heteroatomic ring. An amine functional 
group is found, but can be primary or tertiary. 
The orientation of the rings varies widely and the 
rings may have substituents covalently bonded to 
the ring (see Fig. 1).  
 
Interestingly, halogen atoms (chlorine, bromine) 
found on drugs 2, 4, 6, 8, and 18, are not 
consistent with H1 antagonists throughout.  Other 
functional groups present include ether groups (-
O-) for drugs 3, 6, 7, 8, 9, 10, and 11; and 
carboxyl groups (-C(O)OH) for drug 1. Non-
aromatic heteroatomic rings are also present. To 
visual eye inspection there appears a broad 
range in structure features, however, numerical 
analysis reveals limitations and consistency in 
properties important for pharmacological 
consideration. 
 
The rule of five states that, in general, an orally 
active drug has no more than one violation of the 
following criteria [29]: 1) No more than 5 
hydrogen bond donors (the total number of 
nitrogen–hydrogen and oxygen–hydrogen 
bonds); 2) No more than 10 hydrogen bond 
acceptors (all nitrogen or oxygen atoms); 3) A 
molecular mass less than 500 Daltons, and;  4) 
An octanol-water partition coefficient log P not 
greater than 5.  Interestingly, only drug 9 and 30 
of the antihistamines have only one violation of 
the rule of five, however, all the NSAIDs drugs 
have zero violations of the RO5. Therefore, all 57 
drugs indicated in Table 1 would be considered 
as orally active drugs. This finding indicates 
favorable drug-likeness for all 57 drugs and good 
bioavailability.  This aspect contributing to the 
efficacy of patient use and popularity of clinical 
prescription. 
 
An outlier is an observation that appears to 
deviate markedly from other observations in the 
sample [30,31]. Here, the Grubbs' test, also 
called the ESD method (extreme studentized 
deviate), is utilized to determine whether one of 
the values in the list of molecular properties (see 
Table 1) is a significant outlier from the rest.  
Among the antihistamine compounds (1 to 30) 
only, there is no outlier in Log P values and no 
outlier in the number of rotatable bonds 
properties.  However, for each of the following 
properties there is one outlier detected (value 
indicated): Polar surface area (175.85 
Angstroms2), number of atoms (35), molecular 
weight (500.55), number of oxygen & nitrogen 
atoms (9), number of –OH and –NHn (8), rule of 
five (1), and molecular volume (474.23 
Angstroms3 ). This outcome indicates that the 
molecular properties of common clinical 
antihistamines are highly consistent, with similar 
drug-likeness and bioavailability. 
 
Interestingly, there are no outliers for all 27 
NSAIDs compounds for Log P, polar surface 
area, number of atoms, molecular weight, 
number of oxygen & nitrogen atoms (nON), 
number of –OH & -NHn, rule of five, number of 
rotatable bonds, and molecular volume. This 
clearly shows a strong consistency of the 
NSAIDs in molecular properties, including 
important pharmaceutical properties such as 
drug-likeness and bioavailability.  
 
The mean values for molecular properties, 
inclusive of antihistamine drugs 1 to 30 only, are 
the following, by property: Log P (3.10), polar 
surface area (42.55 Angstroms2), number of 
atoms (22), molecular weight (315.01), number 
of oxygen & nitrogen atoms (~4), number of –OH 
& -NHn (1), rule of five (~0), number of rotatable 
bonds (~6), and molecular volume (294.03 
Angstroms3).  
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The mean values for molecular properties, 
inclusive of NSAIDs drugs 31 to 57 only, are the 
following, by property: Log P (3.27), polar surface 
area (62.94  Angstroms
2
), number of atoms (19), 
molecular weight (274.27), number of oxygen & 
nitrogen atoms (~4), number of –OH & -NHn (~2), 
rule of five (~0), number of rotatable bonds (~3), 
and molecular volume (234.52 Angstroms
3
).  
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Fig. 1. H1 Antagonists compounds 1 (acrivastine), 2 (azelastine), 3 (bromazine),  
4 (brompheniramine), 5 (chlorphenamine), 6 (clemastine), 7 (diphenhydramine),  
8 dexbrompheniramine), 9 (ebastine), 10 (doxylamine), 11 (loratadine), 12 (phenindamine), 
13 (pheniramine), 14 (phenyltoloxamine), 15 (promethazine), 16 (tripelennamine), 
 17 (triprolidine), 18 (chlorpheniramine) 
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Analysis of medians and means of properties 
between drug classes can be achieved by use of 
the Kruskal-Wallis test, one-way ANOVA, and F 
and T tests [30,31]. Analysis of properties in 
Table 1 comparing antihistamines to NSAIDS, 
the Kruskal-Wallis test indicated that Log P and 
number of number of oxygen & nitrogen atoms 
(nON) between the two groups have equal 
medians (P=.35 and P=.26, respectively). One-
way ANOVA indicates equal means in values of 
Log P (P=.64) and nON (P=.62). The F and T 
test indicated equal means of Log P (P=.64), 
comparing antihistamines with NSAIDs (see 
Table 1).  
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Fig. 2. Compounds H1 inverse agonists 19 (cetirizine), 20 (desloratadine), and 21 
(mepyramine).  Compounds H2 antihistamines 22 (cimetidine), 23 (famotidine), 24 
(ranitidine), 25 (roxatidine acetate).  Compounds H3 antihistamines 26 (clobenpropit) and 27 
(ciproxifan).  Compound 28 (thioperamide) is an HRH4 antagonist. Compounds 29 
(catechin) and 30 (tritoqualine) are histidine decarboxylase inhibitor 
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Table 1. Molecular properties of compounds 
 
Drugs Log P Polar 
surface 
area (A
2
) 
Number 
of atoms 
Molecular 
weight 
Number  
O & N 
atoms 
Number 
OH,  NHx 
groups 
Violations of 
rule of 5 
Number 
rotatable 
bonds 
Molecular 
volume 
(Angstroms
3
) 
1   RO6 3.34 53.43 26 348.45 4 1 0 6 335.64 
2 4.82 38.13 27 381.91 4 0 0 3 349.32 
3 4.31 12.47 20 334.26 2 0 0 6 278.66 
4 3.44 16.13 19 319.25 2 0 0 5 265.52 
5 3.31 16.13 19 274.80 2 0 0 5 261.17 
6 4.67 12.47 24 343.90 2 0 0 6 330.38 
7 3.50 12.47 19 255.36 2 0 0 6 260.77 
8 3.44 16.13 19 319.25 2 0 0 5 265.52 
9 6.56 29.54 35 469.67 3 0 1 10 474.23 
10 2.16 25.36 20 270.38 3 0 0 6 272.86 
11 4.58 42.44 27 382.89 4 0 0 2 345.49 
12 3.65 3.24 20 261.37 1 0 0 1 257.76 
13 2.63 16.13 18 240.35 2 0 0 5 247.63 
14 3.94 12.47 19 255.36 2 0 0 6 260.75 
15 4.44 8.17 20 284.43 2 0 0 3 271.62 
16 2.57 19.37 19 255.37 3 0 0 6 260.39 
17 3.47 16.13 21 278.40 2 0 0 4 281.23 
18 3.31 16.13 19 274.80 2 0 0 5 261.17 
19 3.32 53.01 27 388.89 5 1 0 8 354.14 
20 3.53 24.92 22 310.83 2 1 0 0 283.78 
21 2.63 28.60 21 285.39 4 0 0 7 285.94 
22 0.14 88.89 17 252.35 6 3 0 7 231.45 
23 -.11 175.85 20 337.46 9 8 0 7 262.24 
24 0.33 86.26 21 314.41 7 2 0 10 288.97 
25 2.13 67.88 25 348.44 6 1 0 10 338.90 
26 2.67 64.56 20 308.84 4 3 0 8 269.85 
27 2.69 54.99 20 270.33 4 1 0 7 254.24 
28 2.67 43.95 20 292.45 4 2 0 4 281.11 
29 1.37 110.37 21 290.27 6 5 0 1 244.14 
30 3.54 110.97 36 500.55 10 2 1 8 446.15 
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Drugs Log P Polar 
surface 
area (A2) 
Number 
of atoms 
Molecular 
weight 
Number  
O & N 
atoms 
Number 
OH,  NHx 
groups 
Violations of 
rule of 5 
Number 
rotatable 
bonds 
Molecular 
volume 
(Angstroms3) 
31 MO1A 1.87 57.53 10 138.12 3 2 0 1 119.06 
32 3.90 57.53 18 250.20 3 2 0 2 200.33 
33 1.43 63.60 13 180.16 4 1 0 3 155.57 
34 3.77 83.83 19 258.23 5 2 0 4 218.44 
35 3.46 37.30 15 206.28 2 1 0 4 211.19 
36 3.46 37.30 15 206.28 2 1 0 4 211.19 
37 3.38 46.53 17 230.26 3 1 0 3 213.97 
38 3.89 46.53 18 242.27 3 1 0 4 224.83 
39 3.59 54.37 19 254.28 3 1 0 4 234.83 
40 2.79 54.37 18 246.31 3 1 0 4 236.61 
41 3.59 54.37 19 254.28 3 1 0 4 234.83 
42 4.05 37.30 18 244.26 2 1 0 3 220.77 
43 3.99 68.54 25 357.79 5 1 0 4 303.24 
44 2.15 54.37 25 356.42 3 1 0 4 306.98 
45 4.57 49.33 19 296.15 3 2 0 4 238.73 
46 2.20 59.30 19 255.27 4 1 0 3 229.39 
47 0.55 99.60 23 333.37 7 2 0 2 274.29 
48 0.72 99.60 23 353.43 7 2 0 2 281.56 
49 1.94 99.60 22 337.38 7 2 0 2 258.76 
50 2.74 99.60 23 371.83 7 2 0 2 272.30 
51 4.77 49.33 18 241.29 3 2 0 3 227.98 
52 5.63 49.33 19 296.15 3 2 0 3 238.49 
53 5.00 49.33 18 261.71 3 2 0 3 224.95 
54 4.84 49.33 20 281.23 3 2 0 4 226.15 
55 3.61 77.99 26 381.38 5 2 0 4 298.65 
56 2.81 101.23 21 308.31 7 1 0 5 248.17 
57 3.58 62.22 18 262.70 4 2 0 3 220.80 
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Statistical analysis shows that Log P and nON for 
these two groups of drugs have equal means 
and medians. This indicates virtual likeness in 
lipophilicity and hydrogen bond acceptors for 
NSAIDs and antihistamines. Both descriptors 
(Log P and nON) are vital for drug-likeness 
according to the RO5 [29]. The favorable 
bioavailability avails these two groups much, 
aiding pharmacological properties and efficacy 
for clinical prescription as medicinal drugs. 
However, similarity in Log P and nON does not 
dictate like medicinal activity when ingested, 
because pharmacophore sites will dictate their 
biological activity.  
 
One-way ANOVA analysis indicates that polar 
surface area and number of rotatable bonds 
between the two groups of drugs do not have 
equal means (P=.01, P<.001, respectively).  This 
suggests that polar surface area is a vital 
indicator of drug-likeness, represented by nON 
and number of –OH and –NHn [29]. 
 
Drugs 19, 20, and 21 shown in Fig. 2, are H1 
inverse agonists (an agent that binds to the same 
receptor as an agonist but induces a 
pharmacological response opposite to that 
agonist). Drugs 22, 23, 24, and 25 shown in            
Fig. 2, are H2 antihistamines act on H2 histamine 
receptors found primarily in parietal cells of the 
gastric mucosa (reducing secretion of gastric 
acid) [20,21,22]. H2-antihistamines have activity 
as inverse agonists and neutral antagonists 
[21,22]. H3-antihistamine drugs are utilized by 
clinicians to inhibit the action of histamine at the 
H3 receptor, which are primarily found in the 
brain as inhibitory auto receptors found in the 
histaminergic nerve terminals modulating the 
release of histamine [21,22]. H3-antihistamines 
are dissimilar to H1 antihistamines, having 
instead stimulating and cognition-modulating 
effects [21,22]. Drugs 26 and 27 are H3 
antihistamines. Compound 28 is an HRH4 
antagonist. The preferred expression of H4R by 
some immune cells and action in allergic 
inflammation explains the rationale for use of 
anti-H4R antagonists in allergic and immune type 
disorders [32]. Compounds 29 and 30 are 
histidine decarboxylase inhibitors. 
 
Molecular structures of NSAIDs 31 to 57 begin in 
Fig. 3, and are identified by their structural 
features. Drugs 31, 32, 33, and 34 are salicylate 
compounds. Salicylates drugs themselves are 
divided into two groups: acetylated (having –
C(=O)CH3) and non-acetylated [1,2,3]. Aspirin or 
acetylsalicylic acid (33) is acetylated, while 
others such as salsalate (34), salicylic acid (31) 
and diflunisal (32) are non-acetylated. Drugs 35, 
36, 37, 38, 39, 40, 41, and 42 are propionic acid 
derivatives in structure, having (-CH3CHC 
(=O)OH) group.  
 
NSAIDs compounds that are acetic acid 
derivatives are compounds 43 (indomethacin), 
44 (sulindac), and 45 (diclofenac). Whereas drug 
46 (ketorolac) is structurally defined as a 
pyrrolizine-1-carboxylic acid compound. 
 
Various other forms of NSAIDs are presented in 
Fig. 4. Drugs 47, 48, 49, and 50 are enolic acid 
or oxicam derivatives. Unlike most other NSAIDs, 
oxicams are not carboxylic acids. Oxicams are 
tautomeric and can exist as a number of 
tautomers (i.e. keto-enol tautomerism, which a 
chemical equilibrium between a keto form 
(ketone or aldehyde) and an enol (alcohol)).  
 
Fenamates or anthranilic acid derivative 
compounds include 51 (mefenamic acid), 52 
(meclofenamic acid), 53 (tolfenamic acid), and 54 
(flufenamic acid). These NSAIDs are 
characterized by having the group C6H4 
(COOH)(NH-). The remaining COX-2 inhibitors 
(COXIB) compounds include 55 (celecoxib) and 
56 (nimesulide). The remaining NSAID clonixin 
(57) is a pyridine-3-carboxylic acid compound. All 
drugs shown in Fig. 4 have at least one aromatic 
ring or heteroatom arene ring.  
 
3.2 Identification of Similarities by Pattern 
Recognition 
 
Pattern recognition is the process of classifying 
input data into groups or classes based on 
principal characteristics. There are two 
classification methods in pattern recognition: 
supervised and unsupervised classification [30]. 
An unsupervised classification method works by 
finding hidden relationships in data applying 
segmentation or clustering techniques. A 
common unsupervised classification method 
utilized in this study is known as K-means 
clustering analysis [30]. K-means cluster analysis 
aims to partition n observations into a 
predetermined number of clusters, in which each 
observation belongs to the cluster with the most 
similar members [30].  
 
Considered altogether, the 57 antihistamines and 
NSAIDs having properties presented in Table 1 
are analyzed by K-means cluster analysis to 
produce six clusters containing the drugs most 
similar to each other (based on properties in 
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Table 1). The results were as follows, 
antihistamine drugs are in bold to distinguish 
from NSAIDs: 
  
Cluster 1: 1, 2, 6, 11, 19, 25, 43, 44, 55. 
 
Cluster 2: 23, 24, 29, 47, 48, 49, 50, 56. 
 
Cluster 3: 3, 4, 8, 20, 21, 26, 28, 45, 52. 
 
Cluster 4: 5, 7, 10, 12, 13, 14, 15, 16, 17, 18, 27. 
 
Cluster 5: 22, 31, 32, 33, 34, 35, 36, 37, 38, 39, 
40, 41, 42, 46, 51, 53, 54, 57. 
 
Cluster 6: 9, 30. 
OHO
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Fig. 3. Salicylate compounds 31 (salicylic acid), 32 (diflunisal), 33 (aspirin), 34 (salsalate). 
Propionic acid compounds 35 (ibuprofen), 36 (dexibuprofen), 37 (naproxen), 38 (fenoprofen), 
39 (dexketoprofen), 40 (loxoprofen), 41 (ketoprofen), and 42 (flurbiprofen).  Acetic acid 
derivatives are compounds 43 (indomethacin), 44 (sulindac), 45 (diclofenac); with 46 
(ketorolac) as a pyrrolizine-1-carboxylic acid 
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Fig. 4. Enolic acid or oxicam derivative compounds 47 (piroxicam), 48 (meloxicam), 49 
(tenoxicam), and 50 (lornoxicam). Anthranilic acid derivative (fenamates) compounds 51 
(mefenamic acid), 52 (meclofenamic acid), 53 (tolfenamic acid), and 54 (flufenamic acid). COX-
2 inhibitors (COXIBS) compounds 55 (celecoxib) and 56 (nimesulide).  Compound 57 (clonixin) 
is a pyridine-3-carboxylic acid 
 
NSAIDs are highly concentrated in cluster 5, 
however, antihistamines and NSAIDs have 
intermixing in clusters 1, 2, 3, and 5.  This 
indicates that there exists similarities between 
various antihistamine drugs with NSAIDs. For 
cluster 1 the antihistamines drugs 1, 2, 6, 11, 19, 
and 25 are most similar to NSAIDs 43, 44, and 
45 (Acetic acid derivatives).  In cluster 5,  the H2 
antihistamine 22 (cimetidine) is determined to be 
most similar to the bulk of the NSAID                    
drugs (17 total) and those including                
salicylates (31, 32, 33, 34), propionic acid 
compounds (34 to 42), anthranilic                   
acid derivatives  (51, 53, 54), and 57 (clonixin)                 
a pyridine-3-carboxylic acid. Antihistamines                    
9 and 30 are distinct to themselves in                  
cluster 6. 
 
Box plots are visual organizing data for 
identifying outliers and for comparing 
distributions [31]. Box plots provide basic 
information describing distribution of data. A 
numerical distribution with a positive skew would 
have a longer whisker in the positive direction 
than in the negative direction. A boxplot splits the 
data set into quartiles and are useful for 
indicating skewness and presence of outliers in 
the data set. Box and whisker plots are effective 
when large numbers of observations are involved 
and two or more data sets are analyzed [31].   
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The molecular weight and Log P parameters 
constitute one-half of the set of parameters 
described in the Rule of 5 [29]. These two 
properties, along with polar surface area, are 
visualized in box plots comparing these two 
groups of drugs (see Fig. 5).   
 
Observing the box plots for molecular weight 
(MW), the medians are indicated within the box, 
and range by the whiskers. The median and 
mean of MW for antihistamine drugs is 300.65 
daltons and 315.01 daltons, respectively.  
Similarly, for NSAIDs that MW is 258.23 daltons 
and 274.28 daltons, respectively. There is a 
generous overlap of the boxes themselves from 
lower quartile to upper quartile.  
 
Observing the box plots for polar surface area 
(PSA), the medians are indicated within the box, 
and range by the whiskers. The median and 
mean of PSA for antihistamine drugs is 26.98 
Angstroms2 and 42.55 Angstroms2, respectively.  
Similarly, for NSAIDs that PSA is 54.37 
Angstroms
2
 and 62.94 Angstroms
2
, respectively. 
There is a complete overlap of the box and 
whisker for the NSAIDS entirely within the range 
of PSA for antihistamines. This may suggest a 
smaller range in PSA that is suitable for NSAID 
drugs.  
 
Observing the box plots for Log P, the medians 
are indicated within the box, and range by the 
whiskers. The median and mean of Log P for 
antihistamine drugs is 3.33 and 3.10, 
respectively.  Similarly, for NSAIDs that Log P is 
3.58 and 3.27, respectively. There is a generous 
overlap of the boxes themselves, with the entire 
box range for NSAIDs contained within the                 
box and whiskers range for antihistamines              
(see Fig. 5).  
 
Principal coordinates analysis (PCoA) is a 
method to analyze and visualize similarities or 
dissimilarities within a data pool. Principal 
coordinates analysis is also known as metric 
multidimensional scaling, and represents inter-
object (dis)similarity in a low-dimensional, 
Euclidean space [33,34].  PCoA can preserve 
distances generated from any (dis)similarity 
measurements, allowing more flexible handling 
of complex data [33,34]. In addition, 
(dis)similarity matrices calculated from 
quantitative, semi-quantitative, qualitative, or 
mixed variables, all can be analyzed by PCoA 
[33]. Interpretation of a PCoA plot is 
straightforward: objects ordinated closer to one 
another are more similar than objects ordinated 
further away [34]. PCoA is suitable for handling a 
wide range of data [33].  
 
PCoA with 95% ellipses, shown in Fig. 6, analyze 
the properties of Table 1. Here it is clearly shown 
that all drugs, save for 9, 23, 30, and 31, fall 
inside the 95% confidence ellipses.  Drugs 9, 23, 
and 30 are antihistamines, whereas 31 is a 
NSAID, do not adhere to the overall 95% 
confidence ellipses encompassing all other 
drugs.  This outcome suggests that drugs 9, 23, 
30, and 31 are unusual and would not be 
considered into a 95% confidence ellipses based 
on molecular properties (not be within the 
expected 95% confidence of outcomes for these 
types of drugs). This outcome shows a striking 
similarity of molecular properties and consistency 
within each group of drug both separately and 
when consider altogether.  
 
Interestingly, K-means cluster analysis for 
similarity showed drugs 9 and 30 to be most 
similar and found in the same cluster 6 (see 
previous).  However, drugs 23 and 31 were 
found to be more dissimilar and found in two 
separate clusters of cluster 2 and cluster 5, 
respectively. Pattern recognition methods                        
are useful for identifying underlying              
relationships among multivariate data matrix and 
finely identify discrete dissimilarities among its 
members. 
 
By box plot the maximum and minimum values of 
molecular weight, Log P, and polar surface area 
substantially or completely overlaps comparing 
NSAIDs to antihistamines. These three 
properties are represented in the RO5 criteria for 
drug-likeness (polar surface area by nON and 
number of –OH and -NHn) [29]. Again, this 
portends to bio-activity being highly similar in 
nature, however, the mechanism of activity 
governs the realized biological activity which for 
NSAIDs is inhibition of COX-1 and COX-2 
enzymes, and antihistamine activity for allergy 
treatment.  For predicting novel drug structures it 
is important to consider the position of atoms in 
formation of the pharmacophore functional 
group. Simply applying analogous parameters of 
the molecular descriptors is not sufficient to 
ensure the desired biological activity. Each group 
of drugs should be consider separately in order 
to increase the likelihood of acquiring the desired 
biological activity, when applying various 
numerical tools for prediction of pharmacological 
properties.  
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Fig. 5. Boxplots (box and whisker plot) of molecular weight, polar surface area, and Log P; for 
comparison of antihistamines to NSAIDs. The minimum and maximum values indicated by the 
whiskers ends. The first quartile found from the minimum value to the lower box end, the third 
quartile is from upper box end to maximum value. The median indicated by solid line within 
the box itself 
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Fig. 6. Principal coordinates analysis with 95% ellipses for all compounds of Table 1. Closest 
proximity indicates most similar agents. The 95% confidence ellipses is the smallest ellipses 
that will cover 95% of the points. Only drugs 9, 23, 30, and 31 fall outside the 95% ellipses 
 
The neighbor-joining cluster analysis (NJ) is a 
distance based method requiring and based on a 
current distance matrix [35]. NJ finds the least 
distant pair or the closest neighbors and creates 
a new node on the tree joining the two closest 
nodes with the two nodes linked through their 
common ancestral node [35]. Advantages of NJ 
are [35]: fast (suited for large datasets), does not 
require ultra-metric data, suited for datasets 
comprising lineages with largely numerical 
varying rates, and permits correction for multiple 
substitutions.   
 
In this approach to cluster analysis, the objects 
(drugs) are arranged in branches having those of 
highest similarity [35]. The range (length) or 
distance of the individual branches are an 
indicative of the closeness (similarity) of 
individual members. The outcome of NJ analysis 
produced four branches, having drugs as follows 
in order beginning from most distant object 
(antihistamines in bold): 1) drugs 30, 9, 19, 2, 11, 
24 1, 6, 43, 44, 3, 14, 8, 20, 29, 21, 14, 17,10, 5, 
18 7, 14 12, 16, and 13;  2)  23, 55, 50, 48, 47, 
49, 24, 29, 56, 26, 45, 52, 27, 54, 53; 3) 31, 33, 
35, 36, 37, 32, 42, 38, 51;  4) 22, 34, 57, 46, 39, 
41, and 40.   
 
By utilizing NJ, the differences (i.e. dissimilarity) 
between NSAIDs and antihistamines becomes 
apparent. Noticeably, the NSAIDs dominate 
branches 2, 3, and 4.  Antihistamines dominate 
branch 1, with a minimal number found in 
branches 2 and 4 (no antihistamine found in 
branch 3). NJ is able to distinguish these                 
groups into separate groups, which follow 
intuitive reasoning based upon their                   
separate and different biological activity. 
Therefore, even though the molecular                
properties are highly similar, analysis by NJ 
successfully shows an expected departure                      
of similarity that corresponds to their quite 
different biological activity. It is important                         
to understand for future purposes of drug design 
to realize that likeness in molecular properties 
does not assure similar biological activity and 
each group of drugs should be consider 
separately.  
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Fig. 7. Neighbor joining cluster analysis of all 57 compounds shown in Table 1.  Identity of 
drugs most similar to another drug (based on molecular properties) are closest to each other 
and contained within the same branch 
 
To distinguish what drugs are most similar                
by molecular properties is a useful endeavor                
for relating bioavailability. However, the        
pattern recognition methods will not identify 
pharmacological active functional groups within 
the whole of the molecular structure. For both 
NSAIDs and antihistamines, the arrangement of 
atoms, even similar atoms, within the molecular 
framework (i.e. formation of the pharmacophore) 
will dictate the anti-inflammatory or antihistamine 
activity of the drug.   
 
The actual prediction of new molecular structures 
would then be greatly aided by application of 
techniques such as multiple regression, to be 
discussed next. An advantage of multiple 
regression here is the continued use of 
determined molecular properties (see Table 1), 
but with the concurrent calculation of 
accompanying descriptors to match the overall 
framework of the desired pharmacological 
activity (i.e. NSAID or antihistamine).  
 
3.3 Molecular Regression Analysis and 
Prediction 
 
3.3.1 Antihistamines 
 
Multiple regression analysis is a powerful 
technique for predicting the value of a dependent 
variable (or outcome variable) from the known 
value of two or more independent variables, also 
referred to as predictor variables [36,37]. In this 
analysis, the predictors such as Log P and             
polar surface area, have significance as 
pharmaceutical properties.  For compounds 1 to 
30, and utilizing the properties given in Table 1, 
we can form analysis with independent variables 
Log P, polar surface area (PSA), number of 
atoms (nAtoms), number of oxygen & nitrogen 
atoms (nON), number of –OH and –NHn, 
molecular weight (MW), molecular volume (MV), 
and number of rotatable bonds (nRotB):  
 
MW = 16.100 + 19.358(LogP) + 1.145(PSA) – 
10.663(nAtoms) +4.418(nON) –  
8.066(nOHNH) – 3.265(nRotB) + 1.479(MV)   (1) 
 
The relationship (1) shows an R2 of 0.9377, 
indicating the model accounts for 93.77% of the 
variance in dependent variable MW based on the 
model. The independent variables of greatest 
significance are the Log P (P=.02) and molecular 
volume (P=.01). The prediction of novel drug 
structures can be accomplished, with calculation 
of these important properties as each 
independent variable is modified, to get the final 
dependent variable molecular weight (MW).  
 
3.3.2 Non-steroidal anti-inflammatory drugs 
 
For compounds 1 to 30, and utilizing the 
properties given in Table 1, we can form analysis 
with independent variables Log P, polar surface 
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area (PSA), number of atoms (nAtoms), number 
of oxygen & nitrogen atoms (nON), number of –
OH and –NHn, molecular volume (MV), and 
number of rotatable bonds (nRotB):  
 
MW = -55.633 + 2.750(LogP) – 0.2267(PSA) 
+ 9.206(nAtoms) + 8.629(nON) +  
11.892(nOHNH) – 3.055(nRotB) + 
0.4958(MV)                                                (2) 
 
The relationship (2) shows an R
2
 of 0.9740, 
indicating the model accounts for 97.40% of the 
variance in MW based on the model. The 
independent variables of greatest significance 
are the constant (P=.02) and the number of 
atoms (P=.01). Regression coefficients represent 
the mean change in the response variable for 
one unit of change in the predictor variable while 
holding other predictors in the model constant 
[36]. Again, it is now possible to predict 
parameters for novel drugs by inserting the 
appropriate independent variable values, 
followed by solving for the dependent variable 
(MW).  
 
Prediction by multiple regression has been 
shown to be effective in establishing numerical 
values for variables selected by investigators 
[36]. Causality is a different matter, however, and 
it has been demonstrated by NJ that these two 
groups of drugs can be differentiated despite 
their great similarity in various molecular 
properties. The use of multiple regression 
algorithms is effective for generating legitimate 
numerical values based on the model.  However, 
that does not ensure by itself the creation of a 
new drug structure having the same biological 
activity. The position of the atoms is important 
when pursuing a pharmacophore effective for the 
desired biological activity. Nevertheless, the 
consideration of known proven drug designs can 
guide the assimilation of atoms into novel 
structures suitable for clinical usage.  Formation 
of an effective pharmacophore as well as the 
appropriate molecular properties go hand in hand 
in the design of novel drugs.  
 
Pattern recognition methods have much to 
contribute to design of new pharmaceutics. This 
is particularly true for studies involving 
calculation and collation of data that becomes 
easier with the widespread use of computer 
databases, molecular modeling systems, and 
property prediction packages, this for both 
biological and physicochemical fields [38]. The 
wider use and understanding of these methods 
should enhance their utility in drug design [38]. 
4. CONCLUSION 
 
Antihistamines and NSAIDs are two groups of 
drugs highly important for public health. A 
comparison of 30 antihistamines to 27 NSAIDs 
showed important similarities useful for design of 
novel drug structures. One-way ANOVA and 
Kurskal-Wallis test showed that means and 
medians of Log P and number of oxygen & 
nitrogen atoms of these two groups are equal.  
Properties NSAIDs showed high level of 
consistent values, with no outliers for Log P, 
polar surface area, molecular weight, molecular 
volume, and numbers of –OH, -NHn, rotatable 
bonds, and atoms.  However, antihistamines 
showed outliers in all properties except Log P 
and number of rotatable bonds. Multiple 
regression produced algorithms for both groups 
accounting for over 93% of variance in molecular 
weight.  Box plots showed substantial overlap of 
values for the two groups of drugs for molecular 
weight, polar surface area, and Log P. K-means 
cluster analysis showed that members of 
antihistamines are most similar to members of 
NSAIDs. Similarity among members of the two 
groups is visualized in neighbor joining tree 
cluster analysis.  Principal coordinates analysis 
with 98% ellipses showed clearly that all 
members of the 57 drugs studied (save for 9, 23, 
30, 31) would fall within a 95% confidence area 
based upon molecular properties. This study 
reveals relationships between antihistamines and 
NSAIDs useful for understanding their 
pharmacological activity and the design of novel 
molecular structures. 
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